title: Inhibition of cancer cell growth by ruthenium(II) arene complexes.
abstract: Inhibition of the growth of the human ovarian cancer cell line A2780 by organometallic ruthenium(II) complexes of the type [(eta(6)-arene)Ru(X)(Y)(Z)], where arene is benzene or substituted benzene, X, Y, and Z are halide, acetonitrile, or isonicotinamide, or X,Y is ethylenediamine (en) or N-ethylethylenediamine, has been investigated. The X-ray crystal structures of the complexes [(eta(6)-p-cymene)Ru(en)Cl]PF(6) (5), [(eta(6)-p-cymene)RuCl(2)(isonicotinamide)] (7), and [(eta(6)-biphenyl)Ru(en)Cl]PF(6) (9) are reported. They have "piano stool" geometries with eta(6) coordination of the arene ligand. Complexes with X,Y as a chelated en ligand and Z as a monofunctional leaving group had the highest activity. Complexes 5, 6 (the iodo analogue of 5), 9, and 10 (ethylethylenediamine analogue of 9) were as active as carboplatin. Hydrolysis of the reactive Ru-Cl bond in complex 5 was detected by HPLC but was suppressed by the addition of chloride ions. Complex 5 binds strongly and selectively to G bases on DNA oligonucleotides to form monofunctional adducts. No inhibition of topoisomerase I or II by complexes 5, 6, or 9 was detected. These chelated Ru(II) arene complexes have potential as novel metal-based anticancer agents with a mechanism of action different from that of the Ru(III) complex currently on clinical trial.
authors.affiliation: Department of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, U.K.
authors.forename: R E
authors.initials: RE
authors.lastname: Morris
authors.forename: R E
authors.initials: RE
authors.lastname: Aird
authors.forename: P del S
authors.initials: Pdel S
authors.lastname: Murdoch
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: J
authors.initials: J
authors.lastname: Cummings
authors.forename: N D
authors.initials: ND
authors.lastname: Hughes
authors.forename: S
authors.initials: S
authors.lastname: Parsons
authors.forename: A
authors.initials: A
authors.lastname: Parkin
authors.forename: G
authors.initials: G
authors.lastname: Boyd
authors.forename: D I
authors.initials: DI
authors.lastname: Jodrell
authors.forename: P J
authors.initials: PJ
authors.lastname: Sadler
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D018360:Crystallography, X-Ray; D018736:DNA Adducts / Q000737:chemistry; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D015394:Molecular Structure; D009841:Oligonucleotides / Q000737:chemistry; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D012428:Ruthenium; D013329:Structure-Activity Relationship; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D018736:DNA Adducts; D004791:Enzyme Inhibitors; D009841:Oligonucleotides; D009942:Organometallic Compounds; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D012428:Ruthenium